Searched for
BDR PHARMA
BDR Pharma raises Rs 685 crore from multiples, other investorsThe consortium of investors participating along with Multiples include institutional investors such as the investment arm of Times Group, Q...- BDR looking to buy majority stake in drug plant in BelarusBDR will be investing $13 million in the Belarus facility. In addition, it is also investing in setting up a formulation manufacturing unit...
- Multiples Alternate buys into BDR Pharma, invests Rs 750 crET was the first to report in July last year that global and domestic PE funds were in initial discussions to purchase a minority stake in ...
- Mankind, BDR Pharma join hands to launch anti COVID-19 pill MolulifeMankind Pharma on Wednesday said it has joined hands with BDR Pharmaceuticals to launch oral anti-COVID-19 pill Molulife (Molnupiravir) in ...
- BDR Pharma inks license agreement with DRDO to produce COVID-19 drug 2-DGLast month, the Drugs Controller General of India (DCGI) had approved the oral medication for emergency usage as adjuvant therapy in mild t...
- Global private equity funds in talks to purchase minority stake in BDR PharmaceuticalsFunds like the Carlyle Group, Warburg Pincus and TA Associates are engaged in initial discussions, the people added. Investment bank O3 Cap...
- Mankind Pharma inks distribution pact with BDR Pharmaceuticals for COVID drugUnder the alliance, BDR Pharma will be manufacturing and marketing the product under a royalty free, limited and non-exclusive voluntary li...
- BDR Pharma inks licensing pact with Eli Lilly for COVID-19 treatment drugBaricitinib has received restricted emergency use approval, for use in combination with Remdesivir, for treatment of suspected or laborator...
- BDR Pharma launches generic cancer drug in IndiaBDR Pharmaceuticals on Wednesday said it has launched the generic version of Lenvatinib drug for the treatment of various types of cancers ...
- BDR Pharma launches 80 mg version of prostate cancer drug at Rs 24,480 per pack in IndiaThe company had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40 mg enzalutamide in 2017 to tr...
- BDR Pharma to launch 400mg Favipiravir tablets for treating coronavirus patients in IndiaThe company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild ...
- BDR Pharmaceuticals launches Favipiravir under brand name 'BDFAVI' at Rs 63 per tablet in IndiaBDR pharma has received an approval from the DCGI to manufacture Favipiravir to treat mild to moderate patients with COVID-19 symptoms. The...
- Maharashtra's plan to buy drug from Bangladesh irks local companiesIndian firms said that the Bangladeshi company with which Mantralaya is in talks has neither the import licence, nor a manufacturing licenc...
- BDR in pact to make Gilead drug for CiplaIn late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangemen...
- Two Mumbai companies step up work on COVID-19 drug helping in recoveryMumbai-based BDR Pharma, which makes anti-HIV and Hepatitis C medication, and LASA Supergenerics, an active pharmaceutical ingredient maker...
- Carlyle in talks to invest $100 million in BDR PharmaBDR clocked Rs 550-600 crore in revenue and around Rs 120 crore in FY18 EBITDA.
- Two generics makers end battle to copy drugs amid patent debateBoth companies, BDR Pharma and Lee Pharma, had been seeking so-called compulsory licenses that override patents and allow generics firms in...
- Patent office rejects BDR Pharma’s compulsory licensing applicationThe Patent Office rejected BDR’s application on the grounds that the company did not make enough efforts to obtain a voluntary licence for ...
- BDR Pharma seeks cancer drug licenceBDR Pharma has filed an application with the Mumbai Patent Office, seeking compulsory licence to market a crucial cancer drug, dasatinib
- BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drugA BDR Pharma executive said that the firm has applied to sell a generic version of BMS's patented anti-cancer drug Dasatanib at a much lowe...
Load More
